share_log

Guggenheim Maintains Buy on Neurocrine Biosciences, Raises Price Target to $170

Guggenheim Maintains Buy on Neurocrine Biosciences, Raises Price Target to $170

古根海姆维持对Neurocrine Biosciences的买入,将目标股价上调至170美元
Benzinga ·  05/02 14:23

Guggenheim analyst Yatin Suneja maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and raises the price target from $164 to $170.

古根海姆分析师亚廷·苏内哈维持Neurocrine Biosciences(纳斯达克股票代码:NBIX)的买入并将目标股价从164美元上调至170美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发